Received Sep 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
injection site pain; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included seborrheic dermatitis (Seborrheic dermatitis mostly located on her scalp, resolved over a year ago), eosinophilic esophagitis (Eosinophilic esophagitis) and hives (Hives due to allergies to cats and codeine). Concurrent medical conditions included allergic to cats and allergic reaction to analgesics. Concomitant products included levothyroxine sodium (Levothyroxine). On 21-APR-2025, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: injection site pain). The outcome of the injection site pain was resolved. It was unknown if the reporter considered the injection site pain to be related to Shingrix. It was unknown if the company considered the injection site pain to be related to Shingrix. Linked case(s) involving the same patient: US2025AMR119374 Additional Information: GSK receipt date: 20-AUG-2025 Patient experienced short term injection site pain from that injection. Patient was taking Levothyroxine from the year 2000.; Sender's Comments: US-GSK-US2025AMR119374:SAME PATIENT
Medical History/Concurrent Conditions: Allergic reaction to analgesics; Allergic to cats; Eosinophilic esophagitis; Hives (Hives due to allergies to cats and codeine); Seborrheic dermatitis (Seborrheic dermatitis mostly located on her scalp, resolved over a year ago)
Levothyroxine